JP2016510596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510596A5 JP2016510596A5 JP2015561737A JP2015561737A JP2016510596A5 JP 2016510596 A5 JP2016510596 A5 JP 2016510596A5 JP 2015561737 A JP2015561737 A JP 2015561737A JP 2015561737 A JP2015561737 A JP 2015561737A JP 2016510596 A5 JP2016510596 A5 JP 2016510596A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- acid sequence
- amino acid
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims 5
- 101700026522 SMAD7 Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 230000004071 biological effect Effects 0.000 claims 5
- 230000004663 cell proliferation Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 230000001737 promoting effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 230000026683 transduction Effects 0.000 claims 3
- 238000010361 transduction Methods 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 230000005778 DNA damage Effects 0.000 claims 1
- 231100000277 DNA damage Toxicity 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims 1
- 101710149951 Protein Tat Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003172 anti-dna Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000010393 epithelial cell migration Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005937 nuclear translocation Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775252P | 2013-03-08 | 2013-03-08 | |
| US61/775,252 | 2013-03-08 | ||
| PCT/US2014/022052 WO2014138670A1 (en) | 2013-03-08 | 2014-03-07 | Ptd-smad7 therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510596A JP2016510596A (ja) | 2016-04-11 |
| JP2016510596A5 true JP2016510596A5 (enExample) | 2017-03-30 |
| JP6576251B2 JP6576251B2 (ja) | 2019-09-18 |
Family
ID=51492023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561737A Active JP6576251B2 (ja) | 2013-03-08 | 2014-03-07 | ＰＴＤ−Ｓｍａｄ７薬物療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9422352B2 (enExample) |
| EP (1) | EP2964774B1 (enExample) |
| JP (1) | JP6576251B2 (enExample) |
| CN (1) | CN105358704B (enExample) |
| CA (1) | CA2904329C (enExample) |
| IL (1) | IL241190B (enExample) |
| SG (1) | SG11201507045TA (enExample) |
| WO (1) | WO2014138670A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6124791B2 (ja) | 2010-09-22 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | Ｓｍａｄ７の治療的適用 |
| US9422352B2 (en) | 2013-03-08 | 2016-08-23 | The Regents Of The University Of Colorado, A Body Corporate | PTD-SMAD7 therapeutics |
| KR101853923B1 (ko) * | 2016-01-25 | 2018-05-02 | 연세대학교 산학협력단 | Smad 단백질을 포함하는 자가 면역 질환 치료용 조성물, Smad 단백질을 포함하는 융합 단백질, 이를 제조하기 위한 벡터, 및 이의 제조 방법 |
| US20200332302A1 (en) * | 2017-12-30 | 2020-10-22 | The Regents Of The University Of Colorado, A Body Corporate | Therapeutics of ptd-smad7 fusion proteins |
| US20240175866A1 (en) * | 2021-03-10 | 2024-05-30 | National University Corporation Kumamoto University | Method for Detecting Coronavirus Infection |
| EP4401785A4 (en) * | 2021-09-15 | 2025-11-05 | Univ Colorado Regents | SMAD7 POLYPEPTIDE FORMULATIONS |
| WO2023150743A2 (en) * | 2022-02-07 | 2023-08-10 | Aavogen Inc. | Codon-optimized smad7 gene therapy to treat and prevent muscle wasting and to enhance muscle mass |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| ES2091916T3 (es) | 1989-12-21 | 1996-11-16 | Whitehead Biomedical Inst | Metodo para suministrar moleculas en el interior de celulas eucarioticas. |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| AU670316B2 (en) | 1992-07-27 | 1996-07-11 | Pioneer Hi-Bred International, Inc. | An improved method of (agrobacterium)-mediated transformation of cultured soybean cells |
| EP0903408A3 (en) | 1992-08-21 | 2005-11-02 | Biogen, Inc. | Tat-derived transport polypeptide |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5436222A (en) | 1993-03-15 | 1995-07-25 | The Research Foundation Of State University Of New York | Use of platelet factor 4 to treat inflammatory diseases |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| GB2320431B (en) | 1996-12-20 | 2000-08-30 | Johnson & Johnson Medical | Compositions for the treatment of chronic wounds |
| US6251628B1 (en) * | 1997-05-20 | 2001-06-26 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding Smad7 |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| IL138692A0 (en) | 1998-03-27 | 2001-10-31 | Lilly Co Eli | Treatment and prevention of vascular disease |
| US8466134B1 (en) | 1998-06-26 | 2013-06-18 | Athena Neurosciences, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US6998240B2 (en) | 2001-06-11 | 2006-02-14 | Wisconsin Alumni Research Foundation | Screen for selective inhibitors or activators of Smad protein function |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| WO2004022142A1 (en) | 2002-09-06 | 2004-03-18 | 3M Innovative Properties Company | Metering valve for a metered dose inhaler providing consistent delivery |
| KR100472938B1 (ko) | 2002-10-31 | 2005-03-11 | 학교법인 한림대학교 | 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도 |
| CA2542276A1 (en) | 2003-10-16 | 2005-04-28 | The University Court Of The University Of Edinburgh | Control of es cell self-renewal and lineage specification, and medium therefor |
| PL1845942T3 (pl) | 2005-01-14 | 2014-07-31 | Camurus Ab | Preparaty analogu GnRH |
| MX2007012344A (es) | 2005-04-05 | 2007-12-13 | Pioneer Hi Bred Int | Metodos y composiciones para disenar moleculas de acido nucleico para la expresion de polipeptido en plantas usando la desviacion de codon de virus de planta. |
| JP5505760B2 (ja) | 2005-09-27 | 2014-05-28 | ティッシュテク・インコーポレーテッド | 羊膜調製物及び精製組成物及びその使用方法 |
| WO2008105925A2 (en) | 2006-09-01 | 2008-09-04 | Oregon Health & Science University | COMPOUNDS AND METHODS FOR MODULATING β-CATENIN/SMAD-7 INTERACTIONS |
| US20080114287A1 (en) | 2006-11-14 | 2008-05-15 | Kar Neng Lai | Ultrasound Microbubble Mediated Genes Delivery System |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| US8591961B2 (en) | 2008-09-04 | 2013-11-26 | Allergan, Inc. | Aesthetic treatment of scars and aging skin |
| US20110152352A1 (en) | 2008-06-10 | 2011-06-23 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
| US20100184033A1 (en) | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
| JP6124791B2 (ja) | 2010-09-22 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | Ｓｍａｄ７の治療的適用 |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9422352B2 (en) | 2013-03-08 | 2016-08-23 | The Regents Of The University Of Colorado, A Body Corporate | PTD-SMAD7 therapeutics |
-
2014
- 2014-03-07 US US14/201,488 patent/US9422352B2/en active Active
- 2014-03-07 JP JP2015561737A patent/JP6576251B2/ja active Active
- 2014-03-07 SG SG11201507045TA patent/SG11201507045TA/en unknown
- 2014-03-07 CA CA2904329A patent/CA2904329C/en active Active
- 2014-03-07 US US14/773,167 patent/US10456448B2/en active Active
- 2014-03-07 EP EP14761076.0A patent/EP2964774B1/en active Active
- 2014-03-07 WO PCT/US2014/022052 patent/WO2014138670A1/en not_active Ceased
- 2014-03-07 CN CN201480025596.9A patent/CN105358704B/zh active Active
-
2015
- 2015-09-06 IL IL241190A patent/IL241190B/en active IP Right Grant
-
2016
- 2016-07-12 US US15/208,424 patent/US20170000851A1/en not_active Abandoned
-
2019
- 2019-09-26 US US16/584,608 patent/US20200023037A1/en not_active Abandoned
-
2022
- 2022-04-22 US US17/727,579 patent/US20220370560A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ye et al. | TGF-β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis | |
| HRP20201973T1 (hr) | Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti | |
| Merten et al. | Viral vectors for gene therapy and gene modification approaches | |
| JP2013136622A5 (enExample) | ||
| CY1122703T1 (el) | 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων | |
| JP2012041342A5 (enExample) | ||
| JP2014534202A5 (enExample) | ||
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| JP2017518370A5 (enExample) | ||
| JP2015533791A5 (enExample) | ||
| PH12014500865A1 (en) | Compounds and methods for enhancing innate immune responses | |
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| JP2017532343A5 (enExample) | ||
| JP2017511133A5 (enExample) | ||
| IL269187B2 (en) | Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal | |
| RU2016142580A (ru) | Новые способы, полипептиды и их применение | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli | |
| CU20220016A7 (es) | Proteínas de fusión terapéuticas | |
| BR112021016996A8 (pt) | Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana | |
| JP2014506231A5 (enExample) | ||
| MX376011B (es) | Peptidos promotores del crecimiento y usos de los mismos. | |
| CU20110067A7 (es) | Péptidos cíclicos con actividad antineoplásica y antiangiogénica | |
| PH12015502005A1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| JP2013507954A5 (enExample) |